**Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea**

Ahn et al.

Supplemental Digital Content

Table S1. Characteristics of patients with drug-resistant nephrotic syndrome, stratified according to whether complete remission was achieved within 6 months following rituximab infusion

|  |  |  |  |
| --- | --- | --- | --- |
| Characteristic | no CR (n = 16) | CR (n = 7) | *P*-value |
| Sex, male:female | 10:6 | 4:3 | >.99 |
| Age, years | 7.6±3.8 | 12.4±6.7 | .14 |
| Onset of NS, years | 5.1±3.5 | 7.3±4.8 | .28 |
| Duration of NS, years | 2.5±2.5 | 5.1±4.8 | .28 |
| Height Z score | -1.19±1.76 | -0.66±0.99 | .45 |
| Body weight Z score | -0.06±2.07 | -0.04±1.33 | .82 |
| Pathologic diagnosis |  |  |  |
|  Minimal change disease | 7 (43.8) | 2 (28.6) | .53 |
|  FSGS | 5 (31.3) | 5 (71.4) |  |
|  C1q nephropathy | 2 (12.5) | 0 |  |
|  Others | 1 (6.3) | 0 |  |
|  Kidney biopsy not performed | 1 (6.3) | 0 |  |
| Medication at RTX infusion |  |  |  |
| Oral steroids | 14 (87.5) | 7 (100) | >.99 |
| Methylprednisolone pulse | 2 (12.5) | 0 | >.99 |
| Cyclosporine | 11 (68.8) | 2 (28.6) | .17 |
| Tacrolimus | 3 (18.8) | 5 (71.4) | .03 |
| Mycophenolate mofetil | 1 (6.3) | 0 | >.99 |
| Estimated GFR, mL/min/1.73 m2 | 130.1±69.2 | 113.1±48.3 | .72 |
| Urine protein/creatinine ratio, mg/mg | 11.0±14.3 | 2.5±2.5 | .03 |
| Serum albumin, mg/dL | 2.1±0.8 | 3.4±0.7 | .002 |
| Cholesterol, mg/dL | 422±187 | 292±171 | .06 |
| IgG, mg/dL | 329±243 | 416±194 | .36 |
| IgA, mg/dL | 126±64 | 112±90 | .57 |
| IgM, mg/dL | 167±73 | 159±37 | .72 |

Data are given as number, number (frequency), or mean ± standard deviation, as appropriate. CR, complete remission; NS, nephrotic syndrome; FSGS, focal segmental glomerulosclerosis; RTX, rituximab; GFR, glomerular filtration rate; IgG, immunoglobulin G; IgA, immunoglobulin A; IgM, immunoglobulin M